Document Detail

The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy.
MedLine Citation:
PMID:  12202418     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Misoprostol is widely used in combination with mifepristone for medical termination of pregnancy. We studied the endocrine parameters of trophoblast function during medical termination of early pregnancy using mifepristone in combination with oral or vaginal misoprostol. The effect of prolonged misoprostol administration was also examined. METHODS: Thirty-four women, requesting termination of pregnancy and with <or=63 days of amenorrhoea, received 200 mg of mifepristone on day 0, followed by either oral (n = 13) or vaginal (n = 21) administration of 0.8 mg of misoprostol on day 2. In 23 cases misoprostol administration was continued orally for an additional 7 days. Serum samples, collected up to 14 days following the beginning of the treatment, were analysed for hCG, progesterone and mifepristone. RESULTS: hCG and progesterone concentrations continued to increase until day 2. Following misoprostol, hCG and progesterone levels declined by 70.5 +/- 8.8% and 61.3 +/- 16.3% (mean +/- SD) respectively, in 24 h. The percentage decline in hCG correlated inversely (P < 0.05) with the time taken to abort. The peak level of mifepristone measured on day 2 did not correlate with the decline in serum hCG or progesterone. The kinetics of hCG, progesterone and mifepristone were similar in the different treatment groups. CONCLUSIONS: The route and duration of misoprostol administration have no effect on the kinetics of serum hCG or progesterone during medical termination of early pregnancy.
Helena Honkanen; Sirpa Ranta; Olavi Ylikorkala; Oskari Heikinheimo
Related Documents :
3936528 - Outpatient termination of pregnancy: halothane or alfentanil-supplemented anaesthesia.
11281468 - A comparison of isosorbide mononitrate, misoprostol and combination therapy for first t...
15067238 - Second and third medical termination of pregnancy with misoprostol without mifepristone.
12536338 - Coagulation index to distinguish severe preeclampsia from normal pregnancy.
8814598 - Aggravation of gingival inflammatory symptoms during pregnancy associated with the conc...
10370848 - Office management of early induced abortion.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  17     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-30     Completed Date:  2003-03-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  2315-9     Citation Subset:  IM    
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki and Department of Biomedicine, University of Helsinki, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / administration & dosage*,  therapeutic use
Abortion, Induced / methods*
Administration, Intravaginal
Administration, Oral
Chorionic Gonadotropin / blood*
Misoprostol / administration & dosage*,  therapeutic use
Osmolar Concentration
Pregnancy Trimester, First
Progesterone / blood*
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Chorionic Gonadotropin; 57-83-0/Progesterone; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myocardial infarction and third generation oral contraceptives: aggregation of recent studies.
Next Document:  Intrauterine insemination with frozen donor sperm. Pregnancy outcome in relation to age and ovarian ...